Benjamin J. Burke

Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

Ted W. Johnson, Paul Richardson, Simon Bailey et al. · Journal of Medicinal Chemistry · 2014 · 585 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Resensitization to Crizotinib by the Lorlatinib<i>ALK</i>Resistance Mutation L1198F

Alice T. Shaw, Luc Friboulet, Ignaty Leshchiner et al. · New England Journal of Medicine · 2015 · 484 citations · Full text

Medicine, Oncology, Pharmacology +16

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer

Satoshi Yoda, Michael S. Lawrence, Benjamin J. Burke et al. · Cancer Discovery · 2018 · 306 citations · Full text

Medicine, Molecular Medicine, Oncology +16

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P₁ Lactam Moieties as <scp>l</scp>-Glutamine Replacements

Peter S. Dragovich, Thomas J. Prins, Ru Zhou et al. · Journal of Medicinal Chemistry · 1999 · 189 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +16

Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib

Qinhua Huang, Ted W. Johnson, Simon Bailey et al. · Journal of Medicinal Chemistry · 2014 · 118 citations · Full text

Medicine, Oncology, Pharmacology +14